Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

Stock Information for Merrimack Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Merrimack Pharmaceuticals Inc.

Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Reports Full Year 2023 Financial Results
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Reports Second Quarter 2023 Financial Results
 Merrimack Reports First Quarter 2023 Financial Results
Merrimack Reports Full Year 2022 Financial Results
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.